Strategicheskie podkhody k lecheniyu revmatoidnogo artrita


Cite item

Full Text

Abstract

На основании опыта автора и данных многочисленных исследований изложены принципы и современные стратегические подходы клечению такого тяжелого хронического заболевания, как ревматоидный артрит (РА). Лечение РА ориентировано на подавление активности воспаления и прогрессирования заболевания. Для лечения воспалительного процесса применяют симптоматическую терапию нестероидными или стероидными противовоспалительными средствами, а также терапию медленнодействующими базисными противовоспалительными препаратами (БПВП). В соответствии с рекомендациями Ассоциации ревматологов России основными препаратами лечения РА являются метотрексат, лефлуномид и сульфасалазин. БПВП следует назначать как можно раньше - желательно в первые 3 месяца от появления симптомов. В процессе лечения необходим тщательный контроль успешности лечения и переносимости терапии, на фоне оценки реального риска появляющихся побочных эффектов. При недостаточном эффекте терапии следует менять БПВП, режим приема препарата, комбинировать различные БПВП или оптимизировать лечение больных РА путем добавления к терапии генно-инженерных биологических препаратов.

Full Text

Restricted Access

References

  1. Балабанова Р.М. Руководства по внутренним болезням. М., 1997. С. 257-294.
  2. Goodson N, Symmons D. Rheumatoid arthritis in women: still associated with increased mortality. Ann Rheum Dis 2002;61:955-56.
  3. Riise T, Jacobsen BK, Gran JT, et al. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheum 2002;20:123-27.
  4. Kroot EJA, van Leeuwen MA, van Rijswijk MH, et al. No increased mortality in patient with rheumatoid arthritis: up to 10 years of follow-up from disease onset. Ann Rheum Dis 2000;59:954-58.
  5. Kanevskaya MZ, Chichasova NV. Treatment of early rheumatoid arthritis: influence on parameters of activity and progression in long-term prospective study. Ann Rheum Dis 2003;672(Suppl. 1):179.
  6. Nielen MM, van Schaadenburg D, Reesnik HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurement in blood donors. Arthr Rheum 2004;50:380-86.
  7. Шехтер А.Б., Крель А.А., Чичасова Н.В. Клинико-морфологические сопоставления при различных вариантах ревматоидного артрита (по данным пункционных биопсий синовиальной оболочки) // Терапевтический архив. 1985. № 8. С. 90-100.
  8. Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004;63:226-32.
  9. Emery P, Breedveld F, Dougados M, et.al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-97.
  10. Zatarain E, Strand V. Monitoring disease stat- ivity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Nature Clin Pract Rheumatol 2006;2(11):611-18.
  11. Чичасова Н.В. Лечение различных вариантов течения ревматоидного артрита // Московский медицинский журнал. 1997. № 1. С. 21-26.
  12. Han C, Smolen JS, Kavanaugh A, et al. Impact of disease duration and physical function on employment in RA and PsA patients. Arthr Rheum 2006;54(Suppl.):S54.
  13. Emery P, Breedveld FC, Lemmel EM, et al. A comparation of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
  14. Strand V, Cohen S, Shiff M, et al. Treatment of active rheumatoid arthritis with lefluno- mide compared with placebo and methotrexate. Arch Inter Med 1999;159:2542-50.
  15. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double-blind, placebo-controlled trial versus sulfasalasine. Ann Rheum Dis 2001; 60:913-23.
  16. Чичасова Н.В., Чижова К.А., Иголкина Е.В. и соавт. Новый базисный препарат для лечения ревматоидного артрита - (Арава (лефлуномид): опыт многомесячного применения // РМЖ. 2004. Т. 12, 2(202). С. 124-128.
  17. Maillefert JF, Combe B, Goupille P, et al. Long-term structural effects of combination therapy in patients with early rheumatoid arthritis: five-year follow up of a prospective double blind controlled study. Ann Rheum Dis 2003;62:764-66.
  18. Cohen S, Weaver A, Schiff M, et al. Two- year treatment of active RA with leflunomide compared with placebo or methotrexate. Arthritis Rheum 1999;159:2542-50.
  19. Grigor C, Capell H, Stirling A, et.al. Effect of treatment strategy of tight control of rheumatoid arthritis (the T^ORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-69.
  20. Goecor-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strate- суставных или gies in patients with early rheumatoid arthritis (the BeST study): a randomised, controlled trial. Arthr Rheum 2005;52:3381-90.
  21. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single drug in early rheumatoid arthritis: a randomised trial. FIN-RACo Group. Lancet 1999;353:1568-73.
  22. Korpela M, Laansonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from FIN-RACo study. Arthr Rheum 2004; 50:2072-81.
  23. Capell H, Madhok R, Porter D, et al. Combination therapy with sulphasalazine and methotrexate is more effective than either drug alone in rheumatoid arthritis (RA) patients with a suboptimal response to sulphasalazine: result from the doubleblind placebo controlled MASCOT study. Ann Rheum Dis 2007;66:235-41.
  24. Bijlsma JW, Weinblatt ME. Optimal use of the methotrexate: the advantages of tight control. Ann Rheum Dis 2007;66:1409-10.
  25. Verstappen SMM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-49.
  26. Haagsma CJ, van Riel PL, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus methotrexate alone: a randomised open clinical trial in rheumatoid arthrits patients resistant to suylphasalasine therapy. Dr J Rheum 1994;33:1049-55.
  27. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled doubleblind 52 week clinical trial of sulphasalazine and methotrexate with the single components. Ann Rheum Dos 1999;58:220-25.
  28. Stein M, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study. Arthr Rheum 1997;40:1843-51.
  29. Kremer J, et.al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomised, double-blind, placebo-controlled trial. Ann Int Med 2003; 137:726-33.
  30. Kremer J, et al. Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing methotrexate therapy: open label extension of a randomised, double-blind placebo controlled trial. J Rheum 2004;31:1521-31.
  31. Haagsma CJ, van Riel PL, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomsed, controlled, double-blind, 52 week clinical trial. Br J Rheum 1997;36:1082-88.
  32. Hider SL, Silman AJ, Bunn D, et al. Comparing the long term clinical outcome between methotrexate and sulphasalazine prescribed as the first disease modifying antirheumatic drugs in patients with inflammatory polyarthritis. Ann Rheum Dis 2006;65(11):1449-55.
  33. Garards A, et al. Cyclosporine A monotherapy versus cyclosporine A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 2003;62:291-96.
  34. Marchesoni A, et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomised controlled study comparing the combination of cyclosporine A and methotrexate with methotrexate alone. Arthritis Rheum Rheum 2003;42:1545-49.
  35. Grigor C, Capell H., Stirling A, et al. Effect of treatment strategy of tight control of rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-69.
  36. Porter D. Targeting persistent disease activity in early RA: a commentary on the TICORA trial. Int J Adv Rheum 2005;3:2-6.
  37. Albers JM, Paimela L, Kurki P, et al. Treatment strategy, disease activity, and outcome in four cohort of patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:453-58.
  38. Bijlsma JW, Weinblatt ME. Optimal use of the methotrexate: the advantages of tight control. Ann Rheum Dis 2007;66:1409-10.
  39. Verstappen SMM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-49.
  40. Scott DL, Schttenkirchner M, Smolen JS, et al. Efficacy of leflunomide vs placebo vs sulfasalazine in rheumatoid arthritis: effect of disease duration. Arthritis Rheum 1998:41:S155 abstr.
  41. Singh G, Triadafilopoulos G. Epidemilogy of NSAID induced gastrointestinal complication. J Rheum 1999;26(Suppl. 56):18-24.
  42. Goecor-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): a randomised, controlled trial. Arthr Rheum 2005;52:3381-90.
  43. Smolen J, Van der Heijde DM, StClair EW, et al. Prediction of joint damage in patients with early rheumatoid arthritis treated with high- dose methotrexate with or without concomitant infliximab: Results from ASPIRE trial. Arthritis Rheum 2006;54:702-10.
  44. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
  45. Лечение РА. Клинические рекомендации / Под ред Е.Л. Насонова. М., 2006.
  46. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
  47. Saag KG, Teng GG, Pather NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 2008;59:762-84.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies